The European Commission has approved lecanemab, making it the first therapy authorized in Europe to target the underlying process of Alzheimer’s disease rather than only the symptoms. The medicine is sold as Leqembi and is intended for use in the early stages of the disease.
The approval is an important regulatory milestone, but the excerpt makes clear that the practical impact will be limited. Experts say only a very small portion of Alzheimer’s patients are eligible, and the therapy is restricted to mild cognitive impairment in early-stage disease. It is also limited to patients with a specific gene variant because of concerns about side effects such as swelling and bleeding in the brain.
The drug works by targeting amyloid deposits in the brain, which are linked to Alzheimer’s progression. The European Medicines Agency says patients treated with lecanemab showed a slightly lower increase in cognitive and functional decline after 18 months than those who did not receive it. That suggests a slowing effect rather than a cure.
The report is careful not to oversell the result. It notes that previous Alzheimer’s therapies treated symptoms, while lecanemab is the first EU-approved treatment that goes after a causative process. At the same time, it says the drug cannot reverse irreversible brain damage and that a true cure is still not in sight.
The therapy is already authorized in the United States, the UK and Japan, so the European decision brings the bloc into line with other major markets. Even so, the tight eligibility rules mean that most patients will not qualify. In Germany, for example, experts cited in the report estimated that only a small fraction of the 1.2 million people living with Alzheimer’s would be candidates.
So the story is both hopeful and constrained. Europe has approved the first treatment of its kind, but the science remains early and the population that can use it is narrow. For patients and families, the decision represents progress, though not a breakthrough that changes the disease’s reality overnight. The approval also sets up a practical test for health systems. A therapy that only a narrow group can use still requires diagnostic screening, specialist oversight and careful patient selection, which can limit how quickly it reaches clinics.
That is why the report’s caution matters. Lecanemab may represent progress in the science and regulation of Alzheimer’s treatment, but the real-world impact will depend on who qualifies, how often side effects appear and whether health systems can support the monitoring it requires.
